{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:55:46Z","timestamp":1791190546656,"version":"4.1.0"},"reference-count":134,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.critrevonc.2007.04.007","type":"journal-article","created":{"date-parts":[[2007,7,27]],"date-time":"2007-07-27T14:30:32Z","timestamp":1185546632000},"page":"247-262","source":"Crossref","is-referenced-by-count":34,"title":["Renal cancer"],"prefix":"10.1016","volume":"64","author":[{"given":"Enrichetta","family":"Corgna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Betti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Roila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter H.M.","family":"De Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2007.04.007_bib1","unstructured":"WHO. World Health Organization. International classification of diseases, 9th revision. Geneva; 1977."},{"key":"10.1016\/j.critrevonc.2007.04.007_bib2","unstructured":"WHO. World Health Organisation. International Statistical Classification of diseases and related health problems, 10th revision, vols. 1\u20133; 1992\u20131994. 3rd ed. Geneva:WHO; 1994."},{"key":"10.1016\/j.critrevonc.2007.04.007_bib3","series-title":"Cancer incidence, mortality and prevalence in the European Union","author":"Ferlay","year":"1999"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib4","unstructured":"Coleman MP, Babb P, Daniecki P, et al. Cancer survival trends in England and Wales, 1971\u20131995: deprivation and NHS region. Studies in medical and population subjects No. 61. London:The Stationary Office; 1999."},{"key":"10.1016\/j.critrevonc.2007.04.007_bib5","unstructured":"Crocetti E, Capocaccia R, Casella C, et al. Cancer trends in Italy: figures from the cancer registries (1986\u20131997). Epidemiologia e prevenzione, anno 28 (2) Marzo-Aprile Supplemento; 2004."},{"key":"10.1016\/j.critrevonc.2007.04.007_bib6","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide, version 1.0. Lyon: IARC Press. IARC Cancer Base No. 5; 2001."},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2007.04.007_bib7","article-title":"Survival of cancer patients in Europe: the EUROCARE-3 study","volume":"14","author":"Berrino","year":"2003","journal-title":"Ann Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2007.04.007_bib8","doi-asserted-by":"crossref","first-page":"V61","DOI":"10.1093\/annonc\/mdg754","article-title":"EUROCARE-3: survival of cancer patients diagnosed 1990\u201394\u2014results and commentary","volume":"14","author":"Sant","year":"2003","journal-title":"Ann Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2007.04.007_bib9","doi-asserted-by":"crossref","first-page":"v150","DOI":"10.1093\/annonc\/mdg757","article-title":"Electronic availability of EUROCARE-3 data: a tool for further analysis","volume":"14","author":"Roazzi","year":"2003","journal-title":"Ann Oncol"},{"issue":"Suppl. 12","key":"10.1016\/j.critrevonc.2007.04.007_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/028418699432996","article-title":"Survival of cancer patients in Finland 1955\u20131994","volume":"38","author":"Dickman","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/030089169908500502","article-title":"Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL Working Group","volume":"85","author":"Micheli","year":"1999","journal-title":"Tumori"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/oxfordjournals.bmb.a011531","article-title":"Cancers weakly related to smoking","volume":"52","author":"Doll","year":"1996","journal-title":"Br Med Bull"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ucl.2004.01.004","article-title":"Risk factors for adult renal cell carcinoma","volume":"31","author":"Dhote","year":"2004","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib14","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib15","unstructured":"WCRF and AICR. World Cancer Research Fund and American Institute for Cancer Research, Food, Nutrition and Prevention of Cancer: a Global Perspective. American Institute of Cancer Research:Washington; 1997."},{"key":"10.1016\/j.critrevonc.2007.04.007_bib16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00001648-200111000-00018","article-title":"Acetaminophen and the risk of renal and bladder cancer in the general practice research database","volume":"12","author":"Kaye","year":"2001","journal-title":"Epidemiology"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib17","series-title":"Radiation carcinogenesis","first-page":"347","article-title":"Carcinogenic effects of radiation on the human digestive tract and other organs","author":"Land","year":"1986"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2307\/3577477","article-title":"Radiation dose and second cancer risk in patients treated for cancer of the cervix","volume":"116","author":"Boice","year":"1988","journal-title":"Radiat Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib19","series-title":"Risks from radium and thorotrast. Biologic effects of ionizing radiation (BEIR) Report 21","first-page":"7","article-title":"Radium 224 in humans","author":"Spiess","year":"1989"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/oxfordjournals.aje.a009127","article-title":"Risk of cancer and exposure to gasoline vapors","volume":"145","author":"Lynge","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ijc.2910610503","article-title":"International renal-cell cancer study. IV. Occupation","volume":"61","author":"Mandel","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.1979.tb18711.x","article-title":"Mortality experience of insulation workers in the United States and Canada, 1943\u20131976","volume":"330","author":"Selikoff","year":"1979","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib23","first-page":"396","article-title":"Asbestos and cancer: a cohort followed up to death","volume":"44","author":"Enterline","year":"1987","journal-title":"Br J Ind Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0013-9351(87)80200-1","article-title":"Asbestos and renal adenocarcinoma: a case-control study","volume":"42","author":"Maclure","year":"1987","journal-title":"Environ Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ije\/29.2.238","article-title":"Occupational risk factors for urothelial carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Multicenter Urothelial and Renal Cancer","volume":"29","author":"Pesch","year":"2000","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/oem.51.6.426","article-title":"Occupational risk factors for renal cell carcinoma: a case-control study","volume":"51","author":"Auperin","year":"1994","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1464-410X.1995.tb07410.x","article-title":"Occupational risk for renal cell carcinoma. A case-control study based on the New Zealand Cancer Registry","volume":"75","author":"Delahunt","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib28","series-title":"Unusual occurrences as clues to cancer etiology","first-page":"77","article-title":"Development of adenocarcinoma and acquired cystic disease of the kidney in hemodialysis patients","author":"Ishikawa","year":"1987"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/(SICI)1097-0215(19960611)66:6<723::AID-IJC2>3.0.CO;2-1","article-title":"International renal-cell-cancer study. VI. The role of medical and family history","volume":"66","author":"Schlehofer","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0065-230X(08)60742-3","article-title":"Inherited carcinomas of the kidney","volume":"75","author":"Zbar","year":"1998","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJM197909133011107","article-title":"Hereditary renal-cell carcinoma associated with a chromosomal translocation","volume":"301","author":"Cohen","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib32","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1073\/pnas.82.20.6980","article-title":"Translocation of c-myc in the hereditary renal cell carcinoma associated with a t(3;8)(p14.2;q24.13) chromosomal translocation","volume":"82","author":"Drabkin","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0165-4608(87)90059-8","article-title":"Abnormalities at chromosome region 3p12\u201314 characterize clear cell renal carcinoma","volume":"26","author":"Carroll","year":"1987","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0165-4608(86)90066-X","article-title":"Rearrangement of chromosome 3 in renal cell carcinoma","volume":"19","author":"Yoshida","year":"1986","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/327721a0","article-title":"Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma","volume":"327","author":"Zbar","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib36","first-page":"5087","article-title":"Regional loss of chromosome 6 in two urological malignancies","volume":"49","author":"Rukstalis","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0168-9525(98)01558-3","article-title":"The VHL tumour-suppressor gene paradigm","volume":"14","author":"Kaelin","year":"1998","journal-title":"Trends Genet"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib38","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/MCB.19.2.1289","article-title":"Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells","volume":"19","author":"Gorospe","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc885","article-title":"Molecular basis of the VHL hereditary cancer syndrome","volume":"2","author":"Kaelin","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/scdb.2001.0287","article-title":"Oxygen sensors and angiogenesis","volume":"13","author":"Maxwell","year":"2002","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib41","doi-asserted-by":"crossref","first-page":"6282S","DOI":"10.1158\/1078-0432.CCR-050013","article-title":"Genetic basis of cancer of the kidney: disease-specific approaches to therapy","volume":"10","author":"Linehan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ccr.2004.09.006","article-title":"Focus on kidney cancer","volume":"6","author":"Linehan","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-5347(17)35015-2","article-title":"Hereditary papillary renal cell carcinoma","volume":"151","author":"Zbar","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib44","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0002-9440(10)65147-4","article-title":"Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype","volume":"155","author":"Lubensky","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib46","first-page":"1719","article-title":"Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene","volume":"58","author":"Schmidt","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib47","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/sj.onc.1202547","article-title":"Novel mutations of the MET proto-oncogene in papillary renal carcinomas","volume":"18","author":"Schmidt","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib48","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archderm.135.10.1195","article-title":"Birt\u2013Hogg\u2013Dube syndrome: a novel marker of kidney neoplasia","volume":"135","author":"Toro","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib49","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/00000478-200212000-00002","article-title":"Renal tumors in the Birt\u2013Hogg\u2013Dube syndrome","volume":"26","author":"Pavlovich","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","article-title":"Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt\u2013Hogg\u2013Dube syndrome","volume":"2","author":"Nickerson","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib51","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1593::AID-CNCR22>3.0.CO;2-K","article-title":"Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers","volume":"85","author":"Haitel","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib52","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0022-5347(01)62443-1","article-title":"Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma","volume":"160","author":"Kugler","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib53","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<760::AID-CNCR19>3.0.CO;2-Q","article-title":"Telomerase activity in renal cell carcinoma","volume":"83","author":"Yoshida","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00000478-198210000-00007","article-title":"Prognostic significance of morphologic parameters in renal cell carcinoma","volume":"6","author":"Fuhrman","year":"1982","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib55","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.2910430313","article-title":"Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas","volume":"43","author":"Kovacs","year":"1989","journal-title":"Int J Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib56","first-page":"2081","article-title":"Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis","volume":"149","author":"Bugert","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib57","series-title":"Adult and pediatric urology","first-page":"643","article-title":"Renal perirenal and ureteral neoplasms","author":"Jennings","year":"1997"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib58","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-5347(17)44873-7","article-title":"Prognostic factors in metastatic renal carcinoma","volume":"136","author":"Maldazys","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib59","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1200\/JCO.1987.5.6.862","article-title":"Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study","volume":"5","author":"Marshall","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib60","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V75.3.577.577","article-title":"Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia","volume":"75","author":"Da Silva","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib61","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1365-2559.1986.tb02544.x","article-title":"Malignant hypertension due to a renin-secreting renal cell carcinoma\u2014an ultrastructural and immunocytochemical study","volume":"10","author":"Lindop","year":"1986","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib62","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0002-9343(85)90414-0","article-title":"Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma","volume":"78","author":"Dawson","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib63","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1073\/pnas.85.13.4605","article-title":"Human renal carcinoma expresses two messages encoding a parathyroid hormone-like peptide: evidence for the alternative splicing of a single-copy gene","volume":"85","author":"Thiede","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib64","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1158\/0008-5472.CAN-03-1968","article-title":"Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene","volume":"64","author":"Massfelder","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib65","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/canjclin.46.5.284","article-title":"Current management of renal cell carcinoma","volume":"46","author":"Sokoloff","year":"1996","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib66","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1148\/radiology.205.3.9393533","article-title":"Renal cancer: preoperative evaluation with dual-phase three-dimensional MR angiography","volume":"205","author":"Choyke","year":"1997","journal-title":"Radiology"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-5347(17)62331-0","article-title":"The results of radical nephrectomy for renal cell carcinoma","volume":"101","author":"Robson","year":"1969","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib68","series-title":"TNM classification of malignant tumours","first-page":"131","author":"UICC UICC (International Union Against Cancer)","year":"2002"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib69","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0022-5347(17)39992-5","article-title":"Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors","volume":"143","author":"Giuliani","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib70","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/S0022-5347(01)66026-9","article-title":"Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma","volume":"155","author":"Kletscher","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib71","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000019860","article-title":"Real indications for adrenalectomy in renal cell carcinoma","volume":"35","author":"Wunderlich","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0090-4295(98)00117-4","article-title":"Feasibility of adrenalectomy with radical nephrectomy","volume":"52","author":"Kardar","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib73","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-5347(01)64300-3","article-title":"Laparoscopic radical nephrectomy: the Nagoya experience","volume":"158","author":"Ono","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib74","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-5347(01)63693-0","article-title":"Learning curve and conversion to open surgery in cases of laparoscopic adrenalectomy and nephrectomy","volume":"159","author":"Higashihara","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib75","first-page":"1573","article-title":"Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy","volume":"19","author":"Schafhauser","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib76","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1159\/000020050","article-title":"Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group","volume":"36","author":"Blom","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib77","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0022-5347(01)64675-5","article-title":"Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma","volume":"157","author":"Hafez","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib78","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00005392-199805000-00012","article-title":"Nephron sparing surgery for renal cell carcinoma 4cm or less in diameter: indicated or under treated?","volume":"159","author":"Wunderlich","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib79","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0022-5347(05)67896-2","article-title":"Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup","volume":"163","author":"Fergany","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib80","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0022-5347(01)64091-6","article-title":"Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma","volume":"158","author":"Walther","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib81","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0022-5347(17)58429-3","article-title":"The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma","volume":"117","author":"Montie","year":"1977","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib82","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib83","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","article-title":"Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis","volume":"171","author":"Flanigan","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib84","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib85","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0022-5347(17)67120-9","article-title":"An analysis of factors affecting survival in 150 patients with renal carcinoma","volume":"114","author":"Thompson","year":"1975","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib86","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1200\/JCO.1998.16.6.2261","article-title":"Resection of metastatic renal cell carcinoma","volume":"16","author":"Kavolius","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib87","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/1097-0142(19800115)45:2<381::AID-CNCR2820450232>3.0.CO;2-J","article-title":"Surgical treatment of single brain metastasis: factors associated with survival","volume":"45","author":"Galicich","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib88","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0003-4975(02)03803-1","article-title":"Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma","volume":"74","author":"Pfannschmidt","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib89","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0090-4295(98)00562-7","article-title":"Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study","volume":"53","author":"Walther","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib90","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1993.11.7.1368","article-title":"Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up","volume":"11","author":"Minasian","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib91","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.1999.17.9.2859","article-title":"Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer","volume":"17","author":"Pyrhonen","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(98)03544-2","article-title":"Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib93","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.271.12.907","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib94","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib95","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d\u2019Immunotherapie","volume":"338","author":"Negrier","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib96","first-page":"18","article-title":"Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study","volume":"2","author":"Atzpodien","year":"1990","journal-title":"Mol Biother"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib97","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1200\/JCO.1995.13.2.497","article-title":"Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma","volume":"13","author":"Atzpodien","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib98","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib99","first-page":"5810","article-title":"Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases","volume":"48","author":"Cameron","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib100","first-page":"529","article-title":"A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b","volume":"9","author":"Sznol","year":"1990","journal-title":"J Biol Response Mod"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib101","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/1097-0142(19911015)68:8<1699::AID-CNCR2820680808>3.0.CO;2-#","article-title":"A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma","volume":"68","author":"Mittelman","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib102","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cncr.10783","article-title":"Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma","volume":"95","author":"Atzpodien","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib103","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/annonc\/mdf257","article-title":"Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d\u2019Immunotherapie","volume":"13","author":"Negrier","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib104","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2004.06.155","article-title":"Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)","volume":"22","author":"Atzpodien","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib105","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.10842","article-title":"Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996\u20132000","volume":"95","author":"Gez","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib106","first-page":"42","article-title":"Chemotherapy for advanced renal-cell carcinoma: 1983\u20131993","volume":"22","author":"Yagoda","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib107","first-page":"1977","article-title":"Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study","volume":"3","author":"Samuels","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib108","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0022-5347(17)42663-2","article-title":"Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance","volume":"139","author":"Kakehi","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib109","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/01.ju.0000086829.74971.4a","article-title":"Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer","volume":"170","author":"Stadler","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib110","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","article-title":"Systemic therapy for renal cell carcinoma","volume":"163","author":"Motzer","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib111","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib112","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","article-title":"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation","volume":"343","author":"Childs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib113","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2002.08.068","article-title":"Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results","volume":"20","author":"Rini","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib114","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jso.2930090310","article-title":"Current status of the therapy of advanced renal carcinoma","volume":"9","author":"Hrushesky","year":"1977","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib115","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/bjc.1971.31","article-title":"Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer","volume":"25","author":"Bloom","year":"1971","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib116","first-page":"195","article-title":"Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature","volume":"4","author":"Weiselberg","year":"1981","journal-title":"Cancer Clin Trials"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib117","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.10740","article-title":"A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma","volume":"95","author":"Daliani","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib118","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1200\/JCO.2003.01.536","article-title":"Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma","volume":"21","author":"Hernberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib119","article-title":"A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR+IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)","volume":"24","author":"Hudes","year":"2006","journal-title":"J Clin Oncol Annu Meeting Proc"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib120","doi-asserted-by":"crossref","first-page":"6290S","DOI":"10.1158\/1078-0432.CCR-sup-040025","article-title":"The von Hippel-Lindau tumor suppressor gene and kidney cancer","volume":"10","author":"Kaelin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib121","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib123","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.2003.02.005","article-title":"Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group\/Intergroup Trial","volume":"21","author":"Messing","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib124","first-page":"202","article-title":"Adjuvant therapy of renal cell cancer with interferon alfa-2a","volume":"11","author":"Porzsolt","year":"1992","journal-title":"Proc ASCO"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib125","first-page":"318a","article-title":"Adjuvant interferon (IFN) to radical nephrectomy in Robson's stages II and III renal cell cancer (RCC), a multicenter randomized study with some biological evaluations","volume":"16","author":"Pizzocaro","year":"1997","journal-title":"Proc ASCO"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib126","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/sj.bjc.6602443","article-title":"Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)","volume":"92","author":"Atzpodien","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib127","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1464-410X.1973.tb12152.x","article-title":"The value of radiotherapy in the treatment of hypernephroma\u2014a clinical trial","volume":"45","author":"Finney","year":"1973","journal-title":"Br J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib128","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/1097-0142(197311)32:5<1056::AID-CNCR2820320505>3.0.CO;2-M","article-title":"Proceedings: carcinoma of the kidney","volume":"32","author":"Van der Werf-Messing","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00365597709179965","article-title":"Preoperative irradiation in the treatment of renal adenocarcinoma","volume":"11","author":"Juusela","year":"1977","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib130","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0360-3016(87)90283-5","article-title":"Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group","volume":"13","author":"Kjaer","year":"1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib131","first-page":"1601","article-title":"Future strategies in external radiation therapy of renal cell carcinoma","volume":"19","author":"Kortmann","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib132","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1148\/radiology.193.3.7972814","article-title":"Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT","volume":"193","author":"Kao","year":"1994","journal-title":"Radiology"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib133","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0022-5347(01)64305-2","article-title":"Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model","volume":"158","author":"DiBiase","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2007.04.007_bib134","first-page":"1611","article-title":"Radiosurgery for the treatment of brain metastases in renal cell carcinoma","volume":"19","author":"Becker","year":"1999","journal-title":"Anticancer Res"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842807000832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842807000832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T12:08:26Z","timestamp":1587816506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842807000832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S1040842807000832"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2007.04.007","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}